

Thursday 8th November

08.30	<i>Registration</i>	
09.00	STEPHENSON SUITE OPENING WELCOME (President, Eilish Gilvarry) & INTRODUCTION (Julia Sinclair)	
09.15	Women in Addiction <i>Chaired by: Eilish Gilvarry</i> <i>The history of women and alcohol – Moira Plant</i> <i>How far have we come? – Anne Lingford-Hughes</i> <i>A systems perspective to prevention and treatment – Qiana L Brown</i>	
10.45	<i>Refreshments</i>	
	Stephenson Suite	Northumbrian Room
11.15	INVITED SYMPOSIUM: New psychoactive substances: problems and solutions regarding patterns of use, detection and harm reduction <i>Chaired by: Ann McNeil</i> <i>Caught in the Act: The unintended consequences of drug policy on NPS markets and vulnerable user groups - Rob Ralphs</i> <i>Cause and manner of death associated with use of NPS: a population-wide data analysis of the UK since 2007 - Lucy Webb</i> <i>Addressing the challenges of New Psychoactive Substance detection within frontline environments - Oliver Sutcliffe</i> Discussion	DELEGATE SESSION 1: Developing Interventions for Addictions <i>Chaired by: Julia Sinclair</i> <i>Efficacy of a randomized controlled trial of Integrative Couple Treatment for Pathological Gambling (ICT-PG) : 18 month follow-up - Joël Tremblay</i> <i>Behavioural Couples Therapy (BCT) for the treatment of addiction in the UK: can parents with children benefit? – Anne Whittaker</i> <i>Alcohol Intoxication Management Services in the night-time economy are highly acceptable to their users but may not reduce demand on emergency services as expected: A mixed methods study – Andy Irving</i> <i>SUPPORT (South Gloucestershire Pain Review Pilot) Study: a mixed methods evaluation – Joanna Kesten</i>
12.30	<i>Lunch</i>	
	Stephenson Suite	Northumbrian Room
13.15	INVITED SYMPOSIUM: Facilitating and enhancing long-term recovery: Science, policy, and culture <i>Chaired by: Gillian Tober</i> <i>Recovery from alcohol and other drug problems in a nationally-representative sample of U.S. adults: Prevalence, pathways, and predictors - John Kelly</i> <i>Written in the body: What biomarkers reflecting brain-body communication can tell us about addiction and addiction recovery - David Eddie</i> <i>Recovery as a political and cultural movement - Keith Humphreys</i> Discussion	WORKSHOP: <i>Comprehensive, consistent and accurate: How to report research studies in the field of addiction</i> Robert West Susan Michie John Marsden
14.30	<i>Refreshments</i>	
15.00	Annual General Meeting – all members welcome	
15.45	<i>Break</i>	
	Stephenson Suite	
17.30	SOCIETY LECTURE: <i>How the use of new technologies changes the treatment of alcohol use disorders - Dr Antoni Gual</i>	
18.30	VOTE OF THANKS (Ed Day)	
18.35	<i>Society drinks reception</i>	
19.30	<i>Evening buffet/meal</i>	
	Northumbrian Room	
20.45– 22.00	<i>Celebrating Women in Addiction</i> Drs Sharon Cox and Sally Marlow have been asked by the SSA to create a film tribute to many of the outstanding women in the addiction field; past, present and future. You are invited to join them for a sneak preview of some of these films, which will be eventually be hosted on the SSA website.	

Friday 9th November

	Stephenson Suite	Northumbrian Room
08.30	SSA FUNDED RESEARCHERS <i>Chaired by: Matt Hickman</i> <i>What difference does it make? Assessing the impact of take-home naloxone scale up internationally - Andrew McAuley; Fred Yates prize-winner, 2018</i>	DELEGATE SESSION 2: Advancing the Evidence Base <i>Chaired by: Jane Marshall</i> <i>Use of publication procedures to improve research integrity by alcohol and other drug journals - Dennis Gorman</i>
08.50	<i>Disordered gambling: the psychological mechanisms underpinning it - Steve Sharman; SSA Fellow</i>	<i>Abreast of health: feasibility, acceptability and usability of an opportunistic digital alcohol brief intervention in women attending symptomatic breast clinics - Peter Dutey-Magni</i>
09.10	<i>Can THC (Tetrahydrocannabinol) and CBD (Cannabidiol) inform standard cannabis units? – Tom Freeman; SSA Fellow</i>	<i>Preventing return to smoking postpartum (Pres Study) - Development of an evidence based complex intervention for maintaining positive behaviour change - Caitlin Notley</i>
09.30	PLENARY: STEPHENSON SUITE THE ADDICTION DEBATE: This House believes current human models of addiction make preclinical research obsolete <i>Chaired by: Susan Michie</i> (Proposing: Matt Field ; Seconder: Inge Kersbergen . Opposing: Rainer Spanagel ; Second opposer: Véronique Deroche-Gamonet)	
10.45	POSTER VIEWING: Rocket & Invicta rooms (<i>Refreshments available</i>)	
11.45	Lunch	
	Stephenson Suite	Northumbrian Room
12.30	INVITED SYMPOSIUM: Current issues in prescription and over-the-counter medicine abuse, misuse and dependence <i>Chaired by: Catriona Matheson</i> <i>Pregabalin and gabapentin use, misuse and dependence – Marie Claire Van Hout</i> <i>International perspectives on medicines misuse and dependence – Mayyada Wazaify</i> <i>The extent and nature of opioid analgesic dependence in primary care – Richard Cooper</i> Discussion	DELEGATE SESSION 3: Understanding the needs of vulnerable populations <i>Chaired by: Inge Kersbergen</i> <i>Contraception and pregnancy planning needs of women receiving opiate substitution treatment: can community pharmacy fill the gap? - Hannah Family</i> <i>The contribution of substance use in intimate partner violence perpetration in the accounts of men in substance use treatment and their current or ex-female partners - Polly Radcliffe</i> <i>Optics and Illusions of Street Drinking in East London: A thematic analysis - Allan Tyler</i> <i>What, how and who? Perspectives of problem substance use treatment from those experiencing homelessness and precarious housing: Key components and methodological observations - Hannah Carver</i>
13.45	Break	
	Stephenson Suite	Northumbrian Room
14.10	INVITED SYMPOSIUM: New cognitive therapy approaches for cocaine use disorder <i>Chaired by: Ed Day</i> <i>Memory-focused cognitive therapy (MFCT) for cocaine use disorder – John Marsden</i> <i>Cognitive change processes in cocaine use disorder – Camille Goetz</i> <i>Clinical application of Memory-Focused Cognitive Therapy – Tim Meynen</i> Discussion	SPECIAL SESSION: The revolution of depot and implant buprenorphine as ultra-long-acting medications: What products? What benefits? What impact? <i>Chaired by: John Strang</i> <i>RBP-6000, a new Atrigel-based depot buprenorphine: a high-dose blockade subcutaneous depot injection - Chris Bushe</i> <i>CAM-2038, a new liquid-lipid crystal depot buprenorphine: a dose-ranging suite of weekly and monthly subcutaneous depot injections - Fredrik Tiberg</i> <i>Probuphine, a subcutaneous, implantable formulation: constant level of buprenorphine for 6 months – Richard Rosenthal</i> Discussion
15.25	POSTER PRIZES (awarded by Eilish Gilvarry)	
15.30	Refreshments and close	